打开APP

武田药业与Mersana签订价值3亿美元肿瘤ADC药物研发协议

  1. ADC
  2. Mersana
  3. 武田
  4. 肿瘤

来源:生物谷 2015-01-13 18:50

--日本著名医药公司武田制药最近宣布公司已经和肿瘤药物研发公司Mersana Therapeutics公司签订了一项价值达3亿美元的合作研发协议。

2015年1月13日讯 /生物谷BIOON/ --日本著名医药公司武田制药最近宣布公司已经和肿瘤药物研发公司Mersana Therapeutics公司签订了一项价值达3亿美元的合作研发协议。这一协议是建立在两家公司去年四月份达成的合作关系基础上的。

在此次合作中,双方将开展关于抗体药物偶联技术(ADC)的研究。抗体药物偶联技术是近几年来兴起的一种靶向治疗技术,通过将肿瘤药物和特异性抗体偶联起来,使得药物能够特异性富集到特定病灶部位,这一突破一方面能够加强药物在病灶部位的药物浓度以增进药效,另一方面能够保护健康组织不受药物的损伤,降低临床上肿瘤患者的痛苦。

而Mersana公司也不是浪得虚名,公司自成立以来就专注于抗体药物的研发,其开发的Fleximer技术平台能够更好促进肿瘤药物与抗体的偶联。根据协议,武田制药将支付给Mersana公司包括预付款、里程碑资金在内共计3亿美元的经费。众所周知,自从武田药业收购了Millennium Pharmaceuticals公司,组建了自己的肿瘤药物研发系统之后,公司一直寻求扩大公司在肿瘤药物研发领域的实力。而此次协议则为公司达到这一目的提供了最好的契机。据武田公司透露,双方目前已经展开了关于合作药物的一些印证性研究,并可能再选取更多的药物候选分子进入实验。

另一方面,Mersana公司也乐于与武田开展更密切的合作。事实上,自从2014年肿瘤的免疫疗法研究领域持续升温之后,Mersana公司也成为各大生物医药巨头眼中的香饽饽。Mersana公司先后和默克、Endo以及Adimab等重量级生物医药企业建立了合作关系。(生物谷Bioon.com)

详细英文报道:

Oncology biotech Mersana Therapeutics has expanded its relationship withTakeda, forging an agreement to develop targeted cancer drugs with as much as $300 million on the line.

The agreement builds off of an April alliance between the two and focuses on antibody-drug conjugate (ADC) technology, in which cancer-killing chemicals are hitched onto specifically targeted antibodies, allowing them to laser in on malignancies and spare healthy tissues. Mersana's approach to ADCs is built around Fleximer, a proprietary linking technology the biotech says can better attach disparate drugs to their homing antibodies.

And now Takeda is buying into that promise. Under the expanded deal, the pair will work together on Fleximer-powered ADC candidates for cancer, trying out new targets in a collaboration that could pay Mersana up to $300 million in up-front and milestone payments. They've already begun preclinical proof-of-concept studies on a handful of ADCs, and Takeda has in-licensed the program's first drug candidate.

For Takeda, the deal is a chance to get more shots on goal for its growing oncology division, formerly known as Millennium Pharmaceuticals.

"The expansion of our collaboration with Mersana is a testament to the importance of partnership in innovating new treatments for cancer," Takeda's oncology drug discovery chief Christopher Claiborne said in a statement. "Now encompassing multiple therapeutic targets and potential drug candidates, we look forward to further advancing the next-generation of ADCs under our expanded collaboration with Mersana with the goal of bringing new therapies to patients around the world."

Meanwhile, the company is in the midst of an organizational a transition as new CEO Christophe Weber takes the reins, promising a more "stringent" approach to R&D that would focus spending on areas in which Takeda could compete for the lead. Following the same philosophy, the company is working through an efficiency effort that calls for nearly 3,000 job cuts in the U.S. and Europe to save about $1 billion by 2017.

As for Mersana, the biotech's approach to ADC development has made it an in-demand partner, and Merck KGaA, Endo ($ENDP) and Adimab number among its collaborators.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->